image credit- shutterstock
Global Contract Development and Manufacturing Organizations (CDMOs) BioCina and NovaCina, based in Australia, have announced a strategic merger that will create a powerful brand in biopharmaceutical and small molecule contract manufacturing.
The combined company, which will retain the BioCina name, will be fully integrated to provide the market a seamless, end-to-end offering, from cell line development and process development, to clinical and commercial drug substance and sterile fill-finish of drug products.
This new comprehensive suite of services positions BioCina to meet the ever-growing demand for high-quality, integrated manufacturing solutions for clients in the US, Europe, Asia, Australia, and beyond.
The merger integrates BioCina's world-class expertise in process development and manufacturing for the microbial, plasmid DNA, and mRNA modalities at the Adelaide, South Australia facility, with NovaCina's Perth, Western Australia facility, a state-of-the-art sterile fill-finish plant that has produced more than 600 biologic and small molecule products.
BioCina boasts an elite regulatory track record, including approvals from the US FDA, EMA, TGA, and Health Canada. In addition, drug developers will continue to benefit from Australia's preeminent tax incentive of up to 48.5% for CDMO programmes delivered in Australia.
Mark W. Womack, who has successfully led BioCina's explosive growth and development over the last two years, will continue as CEO. Womack is long recognised for his visionary leadership, instilling a truly client-focused culture and delivering exceptionally reliable operational performance across numerous successful organizations. Previously, Womack served as Chief Executive Officer (CEO) of both KBI Biopharma and Stelis Biopharma and as Chief Business Officer of AGC Biologics, where he was instrumental to their expansion.
